KRTX News and Press, Karuna Therapeutics Inc. From 02/27/20

Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chi...

Initial public offerings (IPOs) can be exciting. A stock's debut on the public market is often surrounded by hype and high expectations, and prices can be volatile. Allowing prices to settle and companies to prove themselves is the real path to outsize stock market gains. Investors should und...

AbbVie (NYSE: ABBV ) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket. More news on: AbbVie Inc., Alkermes plc, BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Announces new strategic drug discovery partnership with Charles River Opens new office dedicated to drug discovery and potential development of novel CNS therapeutics Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing n...

Shares of  Karuna Therapeutics  (NASDAQ: KRTX)  rose 26% in January, according to data provided by S&P Global Market Intelligence . However, at $92 a share as of this writing, the stock is still below its all-time high of $124 a share, set less than three months ago. Karuna...

Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...

Shares of Karuna Therapeutics (NASDAQ: KRTX) were sinking 13.3% as of 3:22 p.m. on Thursday after falling as much as 21.1% earlier in the day. The drop came after Karuna's largest shareholder, PureTech Health, submitted a regulatory filing to the Securities and Exchange Commission (SEC) whic...

Today, we will study why BioXcel Therapeutics ( BTAI ) is risky but attractive in 2020. Company overview BioXcel Therapeutics is a clinical-stage biopharmaceutical company focused on deploying AI (artificial intelligence) and machine learning to develop drugs across neurology and immuno-...

Genprex (NASDAQ: GNPX )  -37%  on pricing $8M stock offering. More news on: Genprex, Inc., Applied Genetic Technologies Corporation, Tetraphase Pharmaceuticals, Inc., Stocks on the move, , Read more ...